Scoopfeeds — Intelligent news, curated.
Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?
business

Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?

Yahoo Finance · Jun 28, 2026, 4:45 PM · Also reported by 4 other sources

Key takeaways

  • Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?
  • In a separate development, Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name.
  • Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock.

Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts? Noor Ul Ain Rehman Sun, June 28, 2026 at 11:45 PM GMT+7 1 min read DHR TMO Danaher Corporation (NYSE:DHR) is one of the best non-tech stocks to buy according to analysts. Masimo, Danaher Corporation's (NYSE:DHR) specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, announced on June 22, FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Supported by Masimo's next-generation smartSET™ pulse oximetry sensor platform, the new feature employs advanced pattern recognition, which analyzes continuous physiologic data, allowing clinicians to identify early signs of respiratory compromise in hospital patients receiving opioid therapy.

In a separate development, Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is "a little cheaper on P/E". It added that the Masimo (MASI) transaction "confused us about DHR's identity."

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.

Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance → More top stories

Also covered by

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop